Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Schering supports China haemophilia centres

This article was originally published in Scrip

Executive Summary

Bayer Scheringhas pledged a total of €1.5 million over the next five years to fund the development of haemophilia treatment centres in China. The firm has linked with the Chinese Society of Hematology to provide equipment, supplies and educational materials to, and support patient and nursing programmes at, the six existing centres in the country, where an estimated 70,000 to 100,000 people suffer from the disorder. The aim is to develop the network to provide a full range of services in support of improved diagnosis and treatment. Bayer Schering markets Kogenate, currently the only recombinant Factor VIII product approved in China.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel